GCA
NVO

Greenwood Capital Associates’s Novo Nordisk NVO Stock Holding History

Greenwood Capital Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,451
Closed -$531K – 300
2026
Q1 		$531K Buy
+14,451
New +$685K 0.06% 186
2025
Q3 		– Sell
-56,884
Closed -$3.93M – 267
2025
Q2 		$3.93M Buy
+56,884
New +$3.87M 0.49% 67
2024
Q4 		– Sell
-2,490
Closed -$296K – 254
2024
Q3 		$296K Sell
2,490
-32,974
-93% -$4.4M 0.04% 214
2024
Q2 		$5.06M Buy
35,464
+497
+1% +$65.9K 0.67% 53
2024
Q1 		$4.49M Sell
34,967
-6,428
-16% -$765K 0.6% 59
2023
Q4 		$4.28M Buy
+41,395
New +$4.09M 0.55% 63
2020
Q1 		– Sell
-53,620
Closed -$1.55M – 189
2019
Q4 		$1.55M Sell
53,620
-116,660
-69% -$3.23M 0.33% 68
2019
Q3 		$4.4M Sell
170,280
-1,610
-0.9% -$40.7K 1.07% 35
2019
Q2 		$4.39M Buy
+171,890
New +$4.25M 1.1% 36

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return

Greenwood Capital Associates's NVO Position: Q2 2026 in Review

Greenwood Capital Associates sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 14,451 shares — an estimated $531K sold.

Greenwood Capital Associates first reported a position in NVO in Q2 2019 and held it in 9 quarters. The position peaked at $5.06M in Q2 2024. 516 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Greenwood Capital Associates reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Greenwood Capital Associates sold 14,451 Novo Nordisk shares in Q2 2026, an estimated $531K.
  • Greenwood Capital Associates first reported a position in Novo Nordisk in Q2 2019 and held it in 9 quarters.
  • Greenwood Capital Associates's Novo Nordisk position peaked at $5.06M in Q2 2024.
  • 516 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.